Previous 10 | Next 10 |
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2022 Earnings Conference Call August 03, 2022, 08:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief ...
Alnylam Pharmaceuticals ( ALNY ) made headlines across the biotech space on Wednesday after the RNAi therapeutics company announced that its ATTR amyloidosis therapy patisiran met the main goal in a Phase 3 trial. The much-awaited data readout propelled Alnylam ( ALNY ...
The following slide deck was published by Regeneron Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Regeneron Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation
Regeneron Pharmaceuticals ( NASDAQ: REGN ) traded higher in the pre-market Wednesday after reporting better than expected financials for 2Q 2022 even as the company’s revenue slipped ~44% YoY $2.9B as sales from COVID-19 antibody therapy REGEN-COV dried up. Howeve...
Regeneron Pharmaceuticals press release ( NASDAQ: REGN ): Q2 Non-GAAP EPS of $9.77 beats by $1.02 . Revenue of $2.86B (-44.4% Y/Y) beats by $60M . EYLEA U.S. net sales increased 14% Y/Y to $1.62B. Dupixent global net sales increased 40% ...
Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) PR Newswire First clinical data from ongoing Phase 1/2 trial s...
Regeneron Pharmaceuticals ( NASDAQ: REGN ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is $8.75 (vs. $25.80 last year) and the consensus Revenue Estimate is $2.8B (vs. $5.14B last year). The si...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Recent data from Intellia’s Regeneron collaboration for CRISPR-based NTLA-2001 shows a durable response to the lead in vivo genome editing candidate. Multiple catalysts from new clinical data releases are seen in the coming quarters and years. The company is a buy for aggre...
Senate Democrats introduced a $21B emergency supplemental funding bill on Thursday to respond to the next phase of the pandemic, including the threat of new variants of the coronavirus. The measure unveiled by Senators Patrick Leahy (D-Vt.), Patty Murray (D-Wash.) and Christopher ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...